INTRODUCTION: Patients with metastatic colorectal cancer can develop jaundice from intrahepatic or extrahepatic causes. Currently, there is little data on the underlying causes and overall survival after onset of jaundice. The purpose of this study was to characterize the causes of jaundice and determine outcomes. METHODS: Six hundred twenty-nine patients treated for metastatic colorectal cancer between 2004 and 2010 were retrospectively reviewed. Those developing jaundice were grouped as having intrahepatic or extrahepatic obstruction. Demographics, clinicopathologic, and outcome data were analyzed. RESULTS: Sixty-two patients with metastatic colorectal cancer developed jaundice. Intrahepatic biliary obstruction was most common, occurring in younger patients. Time from metastatic diagnosis to presentation of jaundice was similar between groups, as was the mean number of prior lines of chemotherapy. Biliary decompression was successful 41.7 % of the time and was attempted more commonly for extrahepatic causes. Median overall survival after onset of jaundice was 1.5 months and it was similar between groups, but improved to 9.6 months in patients who were able to receive further chemotherapy. CONCLUSIONS: Jaundice due to metastatic colorectal cancer is an ominous finding, representing aggressive tumor biology or exhaustion of therapies. Biliary decompression is often difficult and should only be pursued when additional treatment options are available.
INTRODUCTION:Patients with metastatic colorectal cancer can develop jaundice from intrahepatic or extrahepatic causes. Currently, there is little data on the underlying causes and overall survival after onset of jaundice. The purpose of this study was to characterize the causes of jaundice and determine outcomes. METHODS: Six hundred twenty-nine patients treated for metastatic colorectal cancer between 2004 and 2010 were retrospectively reviewed. Those developing jaundice were grouped as having intrahepatic or extrahepatic obstruction. Demographics, clinicopathologic, and outcome data were analyzed. RESULTS: Sixty-two patients with metastatic colorectal cancer developed jaundice. Intrahepatic biliary obstruction was most common, occurring in younger patients. Time from metastatic diagnosis to presentation of jaundice was similar between groups, as was the mean number of prior lines of chemotherapy. Biliary decompression was successful 41.7 % of the time and was attempted more commonly for extrahepatic causes. Median overall survival after onset of jaundice was 1.5 months and it was similar between groups, but improved to 9.6 months in patients who were able to receive further chemotherapy. CONCLUSIONS:Jaundice due to metastatic colorectal cancer is an ominous finding, representing aggressive tumor biology or exhaustion of therapies. Biliary decompression is often difficult and should only be pursued when additional treatment options are available.
Authors: S Iwatsuki; I Dvorchik; J R Madariaga; J W Marsh; F Dodson; A C Bonham; D A Geller; T J Gayowski; J J Fung; T E Starzl Journal: J Am Coll Surg Date: 1999-09 Impact factor: 6.113
Authors: Christophe Laurent; Antonio Sa Cunha; Eric Rullier; Denis Smith; Anne Rullier; Jean Saric Journal: J Am Coll Surg Date: 2004-06 Impact factor: 6.113
Authors: Jean-Luc Van Laethem; Sébastien De Broux; Pierre Eisendrath; Michel Cremer; Olivier Le Moine; Jacques Devière Journal: Am J Gastroenterol Date: 2003-06 Impact factor: 10.864
Authors: Giorgio Ercolani; Gian Luca Grazi; Matteo Ravaioli; Walter Franco Grigioni; Matteo Cescon; Andrea Gardini; Massimo Del Gaudio; Antonino Cavallari Journal: Ann Surg Date: 2004-02 Impact factor: 12.969
Authors: Jennifer S Chiang; Nathan Y Yu; Natalie M Ertz-Archambault; Nina J Karlin; Staci N Shoudis; Terence T Sio Journal: J Gastrointest Oncol Date: 2019-12
Authors: Ivan Nikolić; Jelena Radić; Andrej Petreš; Aleksandar Djurić; Mladjan Protić; Jelena Litavski; Maja Popović; Ivana Kolarov-Bjelobrk; Saša Dragin; Lazar Popović Journal: Cancers (Basel) Date: 2022-09-26 Impact factor: 6.575